Orion Corporation (ORNAV.HE) Financial Analysis & Valuation | Quarter Chart
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treat... more
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharma... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $12.79B | Exchange | HEL |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | FI | CEO | Aino Anna Liisa Hurme |
| IPO Date | 2004-10-07 | CAGR | -0.14% |
| Employees | 4,029 | Website | www.orion.fi |
| Div. Yield | 0.33% | Payout Ratio | 44% |
| Buy Back Yield | — | Total Yield | 0.33% |
ORNAV.HE chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $11.70B | P/E | 19.33 | Forward P/E | — | PEG | 0.28 |
| P/S | 36.56 | P/B | 63.68 | P/CF | 258.96 | P/FCF | 391.8 |
| Sales | $2.23B | Sales 1Y | 22.94% | Sales 3Y | 44.8% | Sales 5Y | 83% |
| EPS | $4.68 | EPS 1Y | 52.23% | EPS 3Y | 57.32% | EPS 5Y | 149.01% |
| Sales QoQ | -39.93% | EPS QoQ | -65.41% | Sales QoQ Avg | 10.88% | EPS QoQ Avg | 39% |
| Gross Margin | 64.79% | Operating Margin | 34.11% | Profit Margin | 27.12% | ROCE | 52% |
| ROA | 25% | ROE | 49% | Altman Z Score | 9.13 | Piotroski Score | 6 |
| Current Ratio | 1.77 | Quick Ratio | 1.13 | Cash Ratio | 0.25 | Op. CF Ratio | 0.05 |
| Debt/Equity | 0.29 | Debt/Assets | 0.16 | Lt Debt/Equity | 0.1 | Lt Debt/Cap. | 0.09 |
| Intrst Cov. | 154.84 | Inventory Turnover | 1.34 | Asset Turnover | 0.94 | Receivables Turnover | 2.79 |
| Enterprise Value | $11.70B | P/E Ratio | 19.33 |
| Forward P/E | — | PEG Ratio | 0.28 |
| P/S Ratio | 36.56 | P/B Ratio | 63.68 |
| P/CF Ratio | 258.96 | P/FCF Ratio | 391.8 |
| EPS | $4.68 | EPS Growth 1Y | 52.23% |
| EPS Growth 3Y | 57.32% | EPS Growth 5Y | 149.01% |
| Revenue Growth 1Y | 22.94% | Gross Margin | 64.79% |
| Operating Margin | 34.11% | Profit Margin | 27.12% |
| ROE | 49% | ROA | 25% |
| ROCE | 52% | Current Ratio | 1.77 |
| Quick Ratio | 1.13 | Cash Ratio | 0.25 |
| Debt/Equity | 0.29 | Interest Coverage | 154.84 |
| Altman Z Score | 9.13 | Piotroski Score | 6 |
Orion Corporation (ORNAV.HE) valuation & financials
Orion Corporation (ORNAV.HE) has a market capitalization of $12.79B and trades at a price-to-earnings ratio of 19.3. It operates in the Healthcare sector (Drug Manufacturers - General).
Orion Corporation's revenue grew +22.9% over the last year.
Orion Corporation's next earnings report is scheduled for October 28, 2026 (provider scheduled date); analysts estimate EPS of $1.23. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)